Organic Acids
Medchemexpress LLC Alpha-Melanocyte-Stimulating Hormone TFA | 171869-93-5 | 98.5% | 1 MG
α-MSH TFA (α-Melanocyte-Stimulating Hormone TFA) is an endogenous neuropeptide and a melanocortin receptor 4 (MC4R) agonist. It exhibits anti-inflammatory and antipyretic activities and is a post-translational derivative of pro-opiomelanocortin (POMC).
- Endogenous neuropeptide
- MC4R agonist with anti-inflammatory and antipyretic activities
- Post-translational derivative of pro-opiomelanocortin (POMC)
- Modulates CNS inflammation by acting directly on melanocortin receptors in glial cells
- Modulates NFκB activation
- Inhibits translocation of transcription factor κB to the nucleus
Medchemexpress LLC GIP, rat TFA | 99.8% | 5002.58 | 500 UG
GIP, rat TFA is a bioactive peptide of rat origin, also known as glucose-dependent insulinotropic polypeptide or gastric inhibitory polypeptide. This 42-amino acid peptide is released by K cells in the duodenum and jejunum in response to food intake. As a member of the insulinotropic hormone peptide family, it stimulates insulin secretion from pancreatic beta cells and appears to promote beta cell proliferation and survival. Recent studies suggest that GIP plays a role in lipid homeostasis and may be involved in the pathogenesis of obesity. It is for research use only.
- Bioactive peptide of rat origin
- 42-amino acid peptide
- Stimulates insulin secretion from pancreatic beta cells
- Promotes beta cell proliferation and survival
- Involved in lipid homeostasis and obesity pathogenesis (potential)
- For research use only
Medchemexpress LLC WP9QY (TFA) | 199999-60-5 | 98.7% | 1340.40 | 25 MG
WP9QY TFA is a biologically active cyclic peptide, serving as a TNF-α Antagonist. It is designed to mimic the critical tumor necrosis factor (TNF) recognition loop on TNF receptor I, preventing interactions of TNF with its receptor. This peptide is a useful template for developing small molecular inhibitors to prevent inflammatory bone destruction and systemic bone loss in rheumatoid arthritis. It is for research use only.
- Biologically active peptide
- TNF-α antagonist
- Mimics critical tumor necrosis factor recognition loop on TNF receptor I
- Prevents TNF interactions with its receptor
- Useful template for small molecular inhibitor development
- Prevents inflammatory bone destruction
- Prevents systemic bone loss in rheumatoid arthritis
- For research use only
Medchemexpress LLC Cef20 TFA | 99.3% | 1057.19 | 5 MG
CEF20 TFA is an HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503). It is for research use only.
- An HLA-A*0201-restricted epitope from cytomegalovirus pp65 (495-503)
- For research use only
Medchemexpress LLC GRL-1720 TFA | 2835511-03-8 | C16H12ClF3N2O4 | 25 MG
GRL-1720 TFA is a potent inhibitor of SARS-CoV-2 Mpro with an EC50 value of 15 μM, demonstrating anti-SARS-CoV2 activity. This product appears as a light brown to brown solid with a purity of 98.94% and is intended for research use only.
- Potent inhibitor of SARS-CoV-2 Mpro
- Demonstrates anti-SARS-CoV2 activity
- EC50 value of 15 μM
- Solid appearance
- Light brown to brown color
- Purity of 98.94%
- Intended for research use only
FUJIFILM BIOSCIENCES INC Trifluoroacetic Acid Solution (for Gradient Elution) | 76-05-1 | MFCD00004169 | 40mL
Trifluoroacetic Acid Solution (for Gradient Elution) | Putity: 25% | MW: 114.022 | 76-05-1 | MFCD00004169 | 40mL
Medchemexpress LLC Mtvkpabc-p5 TFA | 98.8% | 1190.22 | C54H74F3N11O16 | 25 MG
MTvkPABC-P5 TFA is the trifluoroacetic acid (TFA) salt of a synthetic Toll-like receptor 7 (TLR7) agonist. It functions as an immune stimulant used in research applications, including the synthesis of immune-stimulating antibody conjugates (ISACs).
- Acts as a TLR7 agonist and immune stimulant.
- Suitable for synthesis of immune-stimulating antibody conjugates (ISACs).
- Provided as a solid TFA salt.
- High purity, 98.8%.
- Molecular weight 1190.22, formula C54H74F3N11O16.
- Available as 25 MG quantity.
Medchemexpress LLC Cilengitide TFA | 199807-35-7 | 99.9% | 702.68 | 25 MG
Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively. It inhibits integrin-mediated binding to vitronectin.
- Potent and selective integrin inhibitor
- Targets αvβ3 receptor with IC50 of 4 nM
- Targets αvβ5 receptor with IC50 of 79 nM
Medchemexpress LLC WP9QY TFA | 99.4% | 1340.40 | 1 MG
WP9QY, a TNF-a Antagonist, is a biologically active peptide.
- This cyclic peptide is designed to mimic the most critical tumor necrosis factor (TNF) recognition loop on TNF receptor I.
- It prevents interactions of TNF with its receptor.
- This TNF antagonist is a useful template for the development of small molecular inhibitors to prevent both inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.
Medchemexpress LLC CCZ01048 TFA | 98.5% | 1622.75 | 5 MG
CCZ01048 TFA is an α-MSH analogue that exhibits high binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM. It shows rapid internalization into B16F10 melanoma cells and demonstrates high in vivo stability, making it a promising candidate for PET imaging of malignant melanoma.
- α-MSH analogue
- High binding affinity to melanocortin 1 receptor (MC1R) with a Ki of 0.31 nM
- Rapid internalization into B16F10 melanoma cells
- High in vivo stability
- Promising candidate for PET imaging of malignant melanoma
Medchemexpress LLC SAH-SOS1A TFA | 2896737-31-6 | 96.6% | 2301.55 | 1 MG
SAH-SOS1A TFA is a peptide-based SOS1/KRAS protein interaction inhibitor. It binds to wild-type and mutant KRAS with nanomolar affinity, directly and independently blocking nucleotide association. This compound impairs KRAS-driven cancer cell viability and exerts its effects by on-mechanism blockade of the ERK-MAPK phosphosignaling cascade downstream of KRAS.
- Peptide-based SOS1/KRAS protein interaction inhibitor
- Binds to wild-type and mutant KRAS (G12D, G12V, G12C, G12S, Q61H) with nanomolar affinity (EC50=106-175 nM)
- Directly and independently blocks nucleotide association
- Impairs cancer cell viability
- Blocks ERK-MAPK phosphosignaling cascade downstream of KRAS
Medchemexpress LLC Wp9qy Tfa | 99.4% | 1340.40 | 5 MG
WP9QY TFA is a biologically active cyclic peptide designed as a TNF-α antagonist. It mimics the critical tumor necrosis factor (TNF) recognition loop on TNF receptor I, thereby preventing interactions of TNF with its receptor. This makes it a useful template for developing small molecular inhibitors to prevent inflammatory bone destruction and systemic bone loss in rheumatoid arthritis.
- Acts as a TNF-α antagonist
- Designed to mimic TNF recognition loop on TNF receptor I
- Prevents TNF interactions with its receptor
- Useful for developing inhibitors for inflammatory bone destruction
- Helps prevent systemic bone loss in rheumatoid arthritis
Medchemexpress LLC Vh4127 TFA | 1034.35 (free base) | 5 MG
VH4127 TFA is a cyclic peptide that targets the low-density lipoprotein receptor (LDLR) with a KD of 18 nM for human LDLR. It specifically binds to the rodent and human epidermal growth factor (EGF) homology domain of LDLR. It is intended for research use only.
- Targets the low density lipoprotein receptor (LDLR)
- High affinity with a KD of 18 nM for human LDLR
- Specifically binds to rodent and human epidermal growth factor (EGF) homology domain of LDLR
- Documentation: data sheet and handling instructions are available
- Formulation: supplied as a solid
- For research use only
Medchemexpress LLC Katacalcin TFA | 99.6% | 2550.62 | 25 MG
Katacalcin TFA (PDN 21 TFA) is a potent plasma calcium-lowering peptide from the calcitonin family. It rapidly decreases blood calcium and phosphate by promoting their incorporation into bones. It also deactivates CD14+ peripheral blood mononuclear cell (PBMC) chemotaxis and regulates their migration.
- Potent plasma calcium-lowering peptide
- Belongs to the calcitonin family
- Promotes incorporation of calcium and phosphate into bones
- More potent inhibitor of fMLP-induced chemotaxis
- Deactivates CD14+ peripheral blood mononuclear cell (PBMC) chemotaxis
- Regulates human CD14+ PBMC migration
Medchemexpress LLC Tat-NR2B9c TFA | 1834571-04-8 | 99.7% | 2632.90 | 25 MG
Tat-NR2B9c TFA is a potent inhibitor of postsynaptic density-95 (PSD-95). It selectively disrupts the interaction between PSD-95 and NMDAR, inhibiting the binding of NR2A and NR2B to PSD-95. This compound also inhibits the interaction between neuronal nitric oxide synthase (nNOS) and PSD-95, demonstrating significant neuroprotective efficacy.
- Potent PSD-95 inhibitor with high affinity for PSD-95d2 (EC50 6.7 nM)
- Inhibits NMDAR2A, NMDAR2B, and NMDAR2C binding to PSD-95
- Blocks interaction between PSD-95 and nNOS
- Reduces infarction volume in vivo